Molecular profile of follicular tumors of the thyroid gland-Reference-Cited by-同舟云学术

Molecular profile of follicular tumors of the thyroid gland

Published:2023-06-01 Issue:1 Volume:13 Page:102-109
ISSN:2411-4634
Container-title:Head and Neck Tumors (HNT)
language:
Short-container-title:Opuholi golovy i šei

Author:

Dolidze D. D.¹^ORCID,Shabunin A. V.¹^ORCID,Сovantsev S. D.²^ORCID,Bagateliya Z. A.¹^ORCID,Kobzev Yu. N.²,Rotin D. L.²,Mulaeva K. A.³^ORCID,Kovaleva M. V.³^ORCID

Affiliation:

1. S.P. Botkin City Clinical Hospital, Moscow Healthcare Department; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

2. S.P. Botkin City Clinical Hospital, Moscow Healthcare Department

3. Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

Abstract

More than 90 % of newly diagnosed cases of endocrine cancer occur in the thyroid gland. Introduction of fine needle puncture of the thyroid gland, with the classification of cytological material according to the Bethesda system, has become the cornerstone of the diagnosis of malignant neoplasms of the thyroid gland. However, traditionally in this classification there remains a weak link called a follicular tumor (category IV). The detection of a follicular tumor in the cytological material does not allow one to reliably classify the mass as benign or malignant and requires surgical intervention with morphological verification. In recent years, the possibilities of molecular genetic testing have improved markedly. Follicular tumors tend to accumulate mutations, which over time can lead to malignant transformation, but can also be used as a method of timely diagnosis. This review analyzes the literature on the possibilities of molecular genetic testing in assessing the malignant potential of follicular formations of the thyroid gland.

Publisher

Publishing House ABV Press

Subject

Pharmacology (medical),Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Otorhinolaryngology,Surgery

Reference41 articles.

1. Поляков А.П., Мордовский А.В., Никифорович П.А. и др. Клинические наблюдения эффективности терапии метастатического радиойодрефрактерного высокодифференцированного рака щитовидной железы мультикиназными ингибиторами. Эндокринная хирургия 2018;12(2):81–8. Polyakov A.P., Mordovsky A.V., Nikiforovich P.A. et al. Clinical observations of the effectiveness of therapy of metastatic radioiodrefract highly differentiated thyroid cancer with multikinase inhibitors. Ehndokrinnaya khirurgiya = Endocrine Surgery 2018;12(2):81–8. (In Russ.).

2. Dolidze D.D., Shabunin A.V., Mumladze R.B. et al. A Narrative Review of preventive central lymph node dissection in patients with papillary thyroid cancer – a necessity or an excess. Front Oncol 2022;12:906695. DOI: 10.3389/fonc.2022.906695

3. Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 2021;71(3):209–49. DOI: 10.3322/caac.21660

4. De Crea C., Raffaelli M., Sessa L. et al. Actual incidence and clinical behaviour of follicular thyroid carcinoma: an institutional experience. Scientific World Journal 2014:952095. DOI: 10.1155/2014/952095

5. WHO classification of tumours of endocrine organs. 4th edn. Ed. by R.V. Lloyd, R.Y. Osamura, G. Kloppel, J. Rosai. 2017. Available at: https://publications.iarc.fr/Book-And-Report-Series/WhoClassification-Of-Tumours/WHO-Classification-Of-Tumours-OfEndocrine-Organs-2017.